Pay in 4 interest-free payments of $6.81 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
The study looking at pioglitazone (PROactive study) failed to show a significant benefit of treatment on the primary composite end points (hazard ratio [HR], 0.90
FeelGood reports that patients on its GLP-1 program lose 15-20% of body weight on average
Even more impressive, over 85% of participants receiving the two highest retatrutide doses achieved complete resolution of steatosis, defined as liver fat content dropping below 5%
Drug-induced lupus erythematosus: an update on drugs and mechanisms
We look forward to additional cardiovascular outcome trials in patients with obesity. The trial was sponsored by Novo Nordisk, the company that markets semaglutide
In the periphery, GLP-1 acts directly on pancreatic islets to enhance GSIS (Mojsov et al., 1987) and inhibit glucagon release (Komatsu et al., 1989)
US$ 27.86
US$ 27.46
US$ 20.12
US$ 20.85
